Irbesartan + Hidroclorotiazida Basi

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Basi, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients when monotherapy is insufficient. The combination works to lower blood pressure by reducing vascular resistance and decreasing fluid volume, offering a synergistic approach for patients with moderate to severe hypertension.

GNH USA supplies Irbesartan + Hidroclorotiazida Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/HCTZ acts on the renin‑angiotensin‑aldosterone system and fluid balance to control elevated blood pressure.

- Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. - Resistant hypertension: adds diuretic effect when an ARB alone does not achieve target blood pressure. - Cardiovascular risk reduction: contributes to decreased risk of stroke and myocardial infarction in hypertensive individuals.

Adverse reactions may occur with any medication. The following list reflects reported events.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Increased urination: more frequent need to void.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Anaphylactic reaction: severe allergic response requiring emergency care.

Before initiating therapy, consider the following safety measures.

- Monitor renal function: assess serum creatinine and eGFR regularly. - Assess electrolytes: watch for hyponatremia, hypokalemia, or hyperkalemia. - Avoid in severe hepatic impairment: use only if benefits outweigh risks. - Pregnancy: risk category unknown; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan/HCTZ can interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase renal risk. - Dual RAAS blockade (e.g., ACE inhibitors, other ARBs): may cause excessive hypotension or kidney injury. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect kidney function. - Lithium: concurrent use can raise lithium concentrations, risking toxicity.